Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.58 |
| ▸ | PI4KA | P42356 | 2/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | GAPDH | P04406 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | STAT6 | P42226 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25389125 | 1.00 | ADORA3 (0.58) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29973013 | 1.00 | ADORA3 (0.58) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24377184 | 1.00 | ADORA3 (0.58) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22220139 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21859152 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30446694 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22220276 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21859283 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13773257 | 0.91 | ADORA3 (0.61) | ADORA3PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24377429 | 0.89 | NT5E (0.49) | ADORA3PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-23 | — | — | US | disclosed |
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
| US-10420788-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-10421771-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | ADORA3 59/4885PI4KA 1437/4885PI4K2B 2234/4885 |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ADORA3 59/4885PI4KA 1437/4885PI4K2B 2234/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | ADORA3 59/4885PI4KA 1437/4885PI4K2B 2234/4885 |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | ADORA3 2598/4885PI4KA 93/4885PI4K2B 110/4885 |
| US-10420788-B2 | — | PNP, ADAR, NT5C2 | ADORA3 61/4885PI4KA 2317/4885PI4K2B 3013/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | ADORA3 1358/4885PI4KA 506/4885PI4K2B 283/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ADORA3 59/4885PI4KA 1437/4885PI4K2B 2234/4885 |
| US-10421771-B2 | — | PNP, ADAR, NT5C2 | ADORA3 61/4885PI4KA 2317/4885PI4K2B 3013/4885 |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | ADORA3 2500/4885PI4KA 91/4885PI4K2B 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.